ENDRA Life Sciences Inc. cash flow to debt ratio of -1.05K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

ENDRA Life Sciences Inc.'s free cash flow has increased -29.89% from $-7.42M last year to $-5.20M, signaling increasing performance

ENDRA Life Sciences Inc.'s debt to equity ratio is 0.26, which means that the company's assets are healthy financed, signaling financial stability.

ENDRA Life Sciences Inc.'s debt has decreased relative to shareholder equity from 0.29 last year to 0.26 today, signaling strengthened financials

ENDRA Life Sciences Inc. has a net cash position, so leverage is healthy.

Interest expense is not separately reported in ENDRA Life Sciences Inc.'s latest filing, so interest coverage cannot be calculated.

ENDRA Life Sciences Inc. has insufficient data to evaluate this check.

ENDRA Life Sciences Inc.'s short-term assets of $967.97K exceed its short-term liabilities of $750.96K

ENDRA Life Sciences Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

ENDRA Life Sciences Inc.'s return on equity of -513.22%, is lower than 15.00%, indicating bad performance

ENDRA Life Sciences Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

ENDRA Life Sciences Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

ENDRA Life Sciences Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

ENDRA Life Sciences Inc. has negative free cash flow, indicating cash burn

ENDRA Life Sciences Inc.'s yearly earnings has increased -38.93% since last year from $-11.51M to $-7.03M, signaling increasing performance

ENDRA Life Sciences Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -236.33% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

ENDRA Life Sciences Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

ENDRA Life Sciences Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

ENDRA Life Sciences Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

ENDRA Life Sciences Inc. has insufficient data to evaluate this check.

ENDRA Life Sciences Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ENDRA Life Sciences Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

ENDRA Life Sciences Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

ENDRA Life Sciences Inc. has insufficient data to evaluate this check.

ENDRA Life Sciences Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ENDRA Life Sciences Inc. has a price-to-book ratio of 2.98x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

ENDRA Life Sciences Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue